11 completed, 2 active not recruiting, 1 withdrawn. 8 Phase 1, 5 Phase 2, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Completed 7, Withdrawn 1 |
| Phase 2 | 5 | Completed 4, Active not recruiting 1 |
| Phase 3 | 3 | Completed 2, Active not recruiting 1 |
Follow BPN14770: new trials by email Literature Review of BPN14770 trials Research Report on BPN14770
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 1 Study of BPN14770 in Participants With Hepatic Impairment and Healthy Controls BPN14770 - Hepatic Impairment | Phase 1 | Completed | Shionogi | 32 | 2025-08-30 | 2026-02-27 |
| Study of BPN14770 in Participants With Severe Renal Impairment and Healthy Controls BPN14770 - Renal Impairment | Phase 1 | Completed | Shionogi | 14 | 2025-08-25 | 2026-02-27 |
| A Study to Assess the Effects of BPN14770 on Rosuvastatin Rosuvastatin, BPN14770 - Healthy Participants | Phase 1 | Completed | Shionogi | 12 | 2025-07-18 | 2025-08-14 |
| Study of Zatolmilast (BPN14770) in Participants With PPP2R5D Neurodevelopmental Disorder (Jordan's Syndrome [JS]) BPN14770, Placebo - Jordan's Syndrome, PPP2R5D Neurodevelopmental Disorder | Phase 2 | Active not recruiting | Shionogi | 30 | 2025-05-13 | 2026-06-09 |
| An Open-Label Extension Study of BPN14770 in Subjects With Fragile X Syndrome Zatolmilast/ BPN14770 - Fragile X Syndrome | Phase 3 | Active not recruiting | Tetra Discovery Partners | 314 | 2022-11-01 | 2025-10-03 |
| A Study of BPN14770 in Male Adults (Aged 18 to 45) With Fragile X Syndrome BPN14770/ zatolmilast, Placebo - Fragile X Syndrome | Phase 3 | Completed | Tetra Discovery Partners | 171 | 2022-11-01 | 2026-07-10 |
| A Randomized Study of BPN14770 in Male Adolescents (Aged 9 to < 18 Years) With Fragile X Syndrome zatolmilast, Placebo - Fragile X Syndrome | Phase 2 / Phase 3 | Completed | Tetra Discovery Partners | 163 | 2022-03-29 | 2026-08-31 |
| A Phase 1, Open-Label, PET Study of T2310 & BPN14770 BPN14770, T2310 - To Determine Brain Target Occupancy of BPN14770 | Phase 1 | Withdrawn | Tetra Discovery Partners | 2020-01-10 | 2022-01-10 | |
| Tetra PICASSO AD Trial: Study to Evaluate Effects of BPN14770 in Early Alzheimer's Subjects BPN14770, Placebo - Alzheimer's Disease | Phase 2 | Completed | Tetra Discovery Partners | 255 | 2019-04-30 | 2025-02-18 |
| Title: Evaluation of a Novel PET Radioligand for Phosphodiesterase-4D (PDE4D) [C-11]T-1650, BPN14770 - Depression | Phase 1 / Phase 2 | Completed | National Institute of Mental Health (NIMH) | 3 | 2019-03-12 | 2021-03-22 |
| A 2-Period Crossover Study of BPN14770 in Adults Males With Fragile X Syndrome BPN14770, Placebo - Fragile X Syndrome, FXS | Phase 2 | Completed | Tetra Discovery Partners | 30 | 2018-07-09 | 2024-12-19 |
| Study to Evaluate the Effects of BPN14770 on Scopolamine-induced Cognitive Impairment in Healthy Volunteers BPN14770, BPN14770 placebo, Donepezil - Alzheimer Disease | Phase 1 | Completed | Tetra Discovery Partners | 38 | 2017-01-01 | 2018-10-16 |
| A Multiple Ascending Dose Study of BPN14770 in Healthy Young and Elderly Male or Female Subjects BPN14770, Placebo - Alzheimer's Disease | Phase 1 | Completed | Tetra Discovery Partners | 77 | 2016-06-01 | 2017-01-18 |
| BPN14770 Single Ascending Dose Study in Healthy Male and Female Subjects BPN14770, Placebo - Alzheimer's Disease | Phase 1 | Completed | Tetra Discovery Partners | 32 | 2015-12-01 | 2017-01-18 |
Alzheimer Disease (4) · Fragile X Syndrome (4) · Dementia (2) · Autism Spectrum Disorder (1) · Autistic Disorder (1) · Brain Diseases (1) · Central Nervous System Diseases (1) · Cognition Disorders (1) · Cognitive Dysfunction (1) · Depression (1) · Developmental Disabilities (1) · Genetic Diseases, Inborn (1) · Learning Disabilities (1) · Mental Disorders (1) · Nervous System Diseases (1)
Tetra Discovery Partners (9) · Shionogi (4) · National Institute of Mental Health (NIMH) (1)
United States (14)
Elizabeth Berry-Kravis, MD (2) · Scott Reines, MD, PhD (2) · Cassandra Key, MD (1) · Paul D Mozley, MD (1) · Robert B Innis, M.D. (1) · Scott Reines, MD (1)